JP2012126750A5 - - Google Patents

Download PDF

Info

Publication number
JP2012126750A5
JP2012126750A5 JP2012081700A JP2012081700A JP2012126750A5 JP 2012126750 A5 JP2012126750 A5 JP 2012126750A5 JP 2012081700 A JP2012081700 A JP 2012081700A JP 2012081700 A JP2012081700 A JP 2012081700A JP 2012126750 A5 JP2012126750 A5 JP 2012126750A5
Authority
JP
Japan
Prior art keywords
molecule
vwf
fviii
proteinaceous
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012081700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012126750A (ja
JP5715983B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012126750A publication Critical patent/JP2012126750A/ja
Publication of JP2012126750A5 publication Critical patent/JP2012126750A5/ja
Application granted granted Critical
Publication of JP5715983B2 publication Critical patent/JP5715983B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012081700A 2004-12-27 2012-03-30 ポリマー−フォンビルブラント因子結合体 Expired - Lifetime JP5715983B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63924404P 2004-12-27 2004-12-27
US60/639,244 2004-12-27
US66837805P 2005-04-04 2005-04-04
US60/668,378 2005-04-04
US67190105P 2005-04-15 2005-04-15
US60/671,901 2005-04-15
US68508605P 2005-05-26 2005-05-26
US60/685,086 2005-05-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007548552A Division JP5022231B2 (ja) 2004-12-27 2005-12-23 ポリマー−フォンビルブラント因子結合体

Publications (3)

Publication Number Publication Date
JP2012126750A JP2012126750A (ja) 2012-07-05
JP2012126750A5 true JP2012126750A5 (enExample) 2013-05-30
JP5715983B2 JP5715983B2 (ja) 2015-05-13

Family

ID=36540284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007548552A Expired - Lifetime JP5022231B2 (ja) 2004-12-27 2005-12-23 ポリマー−フォンビルブラント因子結合体
JP2012081700A Expired - Lifetime JP5715983B2 (ja) 2004-12-27 2012-03-30 ポリマー−フォンビルブラント因子結合体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007548552A Expired - Lifetime JP5022231B2 (ja) 2004-12-27 2005-12-23 ポリマー−フォンビルブラント因子結合体

Country Status (15)

Country Link
US (4) US7884075B2 (enExample)
EP (1) EP1835938B1 (enExample)
JP (2) JP5022231B2 (enExample)
KR (1) KR20070092754A (enExample)
CN (1) CN101163506B (enExample)
AU (1) AU2005322067B8 (enExample)
BR (1) BRPI0519562A2 (enExample)
CA (1) CA2591852A1 (enExample)
DK (1) DK1835938T3 (enExample)
ES (1) ES2434035T3 (enExample)
IL (1) IL183634A (enExample)
MX (1) MX2007007877A (enExample)
PL (1) PL1835938T3 (enExample)
PT (1) PT1835938E (enExample)
WO (1) WO2006071801A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
KR101156263B1 (ko) * 2007-05-18 2012-06-13 박스터 헬쓰케어 에스.에이. 폰 빌리브란트 인자 프로펩티드로부터 성숙한 폰 빌리브란트 인자를 제조하는 방법
PL2167117T3 (pl) * 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
TWI569810B (zh) 2007-06-26 2017-02-11 巴克斯歐塔公司 可水解之聚合茀基甲氧基羰基－連接劑
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
KR101627157B1 (ko) * 2007-12-27 2016-06-03 박스알타 인코퍼레이티드 샘플 내의 재조합 단백질로부터 혈장-유래 단백질의 분별 방법
US8557534B2 (en) 2007-12-27 2013-10-15 Baxter International Inc. Method and compositions for specifically detecting physiologically acceptable polymer molecules
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
TWI492951B (zh) 2007-12-31 2015-07-21 Baxter Int 表現人類凝血因子的基因轉殖非人類動物及其用途
MX2010012044A (es) * 2008-05-06 2011-05-19 Octapharma Ag Complejo que comprende proteinas de union a heparina y conjugados de heparina-almidon de hidroxialquilo.
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
PT2349342T (pt) * 2008-10-17 2018-10-26 Baxalta Inc Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
MX2011004195A (es) * 2008-10-20 2011-09-27 Usv Ltd Un proceso mejorado para la pegilacion de proteinas.
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
JP5568091B2 (ja) * 2008-12-11 2014-08-06 バクスター・インターナショナル・インコーポレイテッド 近赤外分光法を用いた生理学的に許容されるポリマー分子の検出
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US20110072524A1 (en) * 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
MX2012002129A (es) 2009-08-20 2012-06-08 Baxter Int Purificacion del factor de von willebrand (vwf) para remocion incrementada de virus envueltos sin lipido.
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
TWI534152B (zh) 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
KR101309566B1 (ko) * 2010-12-10 2013-09-17 포항공과대학교 산학협력단 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
EP3875106A1 (en) * 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
EP3158055B1 (en) 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
CN104491917B (zh) * 2014-12-30 2018-01-09 广州市拜特凇医药科技有限公司 一种含有peg或其衍生物的生物材料
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
JP2015155469A (ja) * 2015-06-01 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｆｖｉｉｉ因子ポリマー結合体
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
EP3672644A1 (en) 2017-08-23 2020-07-01 CSL Behring GmbH Method for virus filtration of von willebrand factor
JP2018115170A (ja) * 2018-03-02 2018-07-26 バクスアルタ ゲーエムベーハー 第ｆｖｉｉｉ因子ポリマー結合体
CA3094644A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
AU2297792A (en) 1991-06-28 1993-01-25 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic polypeptides based on von willebrand factor
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6127153A (en) * 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AT405740B (de) 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6455639B1 (en) * 1998-03-24 2002-09-24 Nof Corporation Oxirane derivative and process for the preparation thereof
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
AU6357900A (en) * 1999-07-20 2001-02-05 Amgen, Inc. Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
SE515295C2 (sv) 1999-11-23 2001-07-09 Medicarb Ab Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat
AUPR610501A0 (en) 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
EP1673453A2 (en) 2003-10-07 2006-06-28 Novo Nordisk Health Care AG Hybrid molecules having factor vii/viia activity
US9539337B2 (en) 2003-12-10 2017-01-10 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates

Similar Documents

Publication Publication Date Title
JP2008525491A5 (enExample)
JP6527114B2 (ja) 組換えフォンウィルブランド因子の投与による凝固疾患の治療
JP6095717B2 (ja) Ｔｆｐｉインヒビターおよび使用法
RU2719562C2 (ru) Пептидные дендримеры, содержащие фибриноген-связывающие пептиды
JP5870088B2 (ja) 共役血液凝固第ｖｉｉｉ因子
JP7071093B2 (ja) 血液凝固タンパク質複合体
RU2012106150A (ru) Вариантные формы уратоксидазы и их применение
MXPA05009169A (es) Conjugados de polimero-porcion del factor viii.
TW201247709A (en) Therapeutic proteins with increased half-life and methods of preparing same
TW201103562A (en) Blood coagulation protein conjugates
JP2008525491A (ja) ポリマー−フォンビルブラント因子結合体
AU2017213440A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
AU2016362606A1 (en) Factor VIII with extended half-life and reduced ligand-binding properties
US20180140737A1 (en) Haemostatic material
JP2017509602A (ja) ペプチド及びその使用方法
HK1127300A (en) Pegylated factor viii